Traditional risk factors and prior CV disease aren’t the whole story when it comes to increased rates of all-cause mortality in patients with NVAF, say these researchers. Here’s what ...

Expert Rev Cardiovasc Ther. 2012;10(4):433-439. Another important trial that needs discussion is the ROCKET AF trial. ROCKET AF studied 14,264 patients with nonvalvular AF and compared the Factor ...

Data from a Japanese registry may be useful for characterizing frailty among older patients with nonvalvular atrial fibrillation (NVAF), possibly opening the door to better treatment decisions and ...

Background: Too few patients with nonvalvular atrial fibrillation (NVAF) receive appropriate antithrombotic therapy. We tested the short-term (primary outcome) and long-term (secondary outcome) effect ...

Nonvalvular Atrial Fibrillation and Risk of Stroke Rajat Deo, MD, assistant professor of medicine at the University of Pennsylvania Atrial fibrillation is a common arrhythmia.

Cite this: Anticoagulants for Nonvalvular Atrial Fibrillation (NVAF) -- Drug Review - Medscape - Feb 07, 2003. Abstract and Introduction Methodologic Problems in the Randomized Controlled Trials ...

Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 Blood Pressure Control Key Factor in Stroke Risk ...

Nonvalvular A-Fib Management Program Launched by ACP. September 25, 2014 (HealthDay News) — A new program is being developed to help patients recognize the signs and symptoms of ...

Background: Nonvalvular atrial fibrillation (AF) is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment.